In this episode, Dr. Wayne Hogrefe and Dr. Pat Hurban discuss the use of NGS in the development and assessment of new vaccines against the influenza virus.

Topics covered include:

• What health organizations are looking for that drives the selection of the next season's vaccine strains
• How sequence data is used to evaluate the effectiveness of a vaccine while providing insight into the evolution of the virus
• How the sequence data can inform the development of new types of vaccines and therapeutics
• The prospects for a vaccine that is effective across multiple strains and multiple seasons
• How NGS data differs from traditional Sanger sequencing data and what can be learned from that

You can learn more about this topic at www.q2labsolutions.com